Zafar Malik
Clatterbridge Cancer Centre NHS Foundation Trust(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment, Cancer Treatment and Pharmacology, Advanced Radiotherapy Techniques
Most-Cited Works
- → Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy(2017)1,740 cited
- → Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial(2016)1,289 cited
- → Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial(2018)1,235 cited
- → Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial(2019)395 cited
- → 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial(2019)278 cited
- → Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol(2018)246 cited
- → Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial(2015)150 cited
- → Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial(2022)115 cited
- → Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol(2023)90 cited
- → Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial(2017)88 cited